|Bid||127.91 x 0|
|Ask||127.92 x 0|
|Day's Range||126.90 - 129.50|
|52 Week Range||58.01 - 199.40|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||18.86|
|Earnings Date||Oct 28, 2020|
|Forward Dividend & Yield||0.10 (0.08%)|
|Ex-Dividend Date||Jul 07, 2020|
|1y Target Est||100.77|
China's BGI Genomics Co said on Tuesday it expects first-half net profit to be about eight times the amount reported in the same period last year after the global pandemic created a surge in demand for its coronavirus test kits. The genomics company, which said it has distributed more than 35 million kits across 180 countries and regions, forecasted a net profit of between 1.53 to 1.63 billion yuan ($218.32-$232.66 million) in the six months to end-June, a jump of around 700% from 198 million yuan a year ago. The novel coronavirus, which first emerged in China late last year, has to date infected over 13 million people globally and killed more than 575,000.
BGI Genomics announced that its Real-time fluorescent RT-PCR kit for detecting 2019-nCoV has been listed as eligible for World Health Organization (WHO) procurement under the WHO Emergency Use Listing (EUL) process.
BGI Genomics Co., Ltd. (SZSE:300676), and Saudi Arabia's National Unified Procurement Company (NUPCO) have signed an agreement to establish Six "Huo-Yan" ("Fire Eye") laboratories in Saudi Arabia to fight the COVID-19 pandemic. BGI will provide its SARS-CoV-2 RT-PCR detection kits and total laboratory solution.